Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals announced the first release of EoEHSS sub scores data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The data showed significant improvements in esophageal tissue inflammation and fibrosis at both 12 and 36 weeks, especially at the highest dose cohort. These findi…